TiGenix CEO Confident Of European Green Light For Lead Asset

TiGenix CEO Eduardo Bravo outlines group's commercialization plans for CPF candidate Cx601 in Europe and the US.

Green light
TiGenix CEO Confident CPF Candidate Cx601 Will Advance • Source: Shutterstock

TiGenix NV's CEO feels sure the pipeline-stage company's lead asset - a cell-based treatment for complex perianal fistula - can get a go-ahead recommendation next month for Europe, and is already finalizing commercialization plans with Takeda Pharmaceutical Co. Ltd., its partner for the drug in the region.

Eduardo Bravo told Scrip that he is "confident" TiGenix has provided evaluators at the European Medicines Agency what is needed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip